Radotinib
- Generic Name
- Radotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C27H21F3N8O
- CAS Number
- 926037-48-1
- Unique Ingredient Identifier
- I284LJY110
- Background
Radotinib is under investigation for the treatment of Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
- Indication
Radotinib is indicated for the treatment of different types of cancer, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other Bcr-Abl tyrosine-kinase inhibitors, such as patients resistant or intolerant to imatinib.
- Associated Conditions
- -
- Associated Therapies
- -
Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)
- Conditions
- Interventions
- First Posted Date
- 2018-10-29
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 238
- Registration Number
- NCT03722420
- Locations
- 🇨🇳
Peking University People's Hospital(北京大å¦äººæ°‘医院), Beijing, China
Radotinib as 3rd or Later Line Therapy in CP-CML
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Ulsan University Hospital
- Target Recruit Count
- 73
- Registration Number
- NCT02422719
- Locations
- 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI
- Conditions
- Interventions
- First Posted Date
- 2012-05-21
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT01602952
- Locations
- 🇰🇷
Seoul St. Mary's hospital, Seoul, Seocho-gu, Korea, Republic of
🇹ðŸ‡Local institution, Bangkok, Phyathai, Thailand
Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phase Patients
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Il-Yang Pharm. Co., Ltd.
- Target Recruit Count
- 242
- Registration Number
- NCT01511289
- Locations
- 🇹ðŸ‡
Local Institution, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.